跳至主要内容
临床试验/NCT04092712
NCT04092712已完成1 期

A Phase 1, Open-label Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of Oral [14C]-CTP-543 in Healthy Adult Male Subjects

Concert Pharmaceuticals1 个研究点 分布在 1 个国家目标入组 6 人开始时间: 2019年9月5日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
发起方
入组人数
6
试验地点
1
主要终点
CTP-543 metabolite PK: Tmax

研究概览

简要总结

This study will assess the absorption, metabolism, excretion, mass balance, safety, and tolerability of a single oral administration of [14C]-CTP-543 in healthy male subjects.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Basic Science
盲法
None

入排标准

年龄范围
19 Years 至 55 Years(Adult)
性别
Male
接受健康志愿者

入选标准

  • Healthy male subjects between the ages of 19 and 55 years, inclusive (healthy is determined by medical evaluation, including medical history, full physical examination, vital signs, electrocardiogram, and clinical laboratory tests)
  • Body Mass Index of 18.0 to 32.0 kg/m2
  • Continuous non smoker who has not used nicotine containing products for at least 3 months prior to dosing and throughout the study

排除标准

  • Known immunodeficiency disorder, including positive serology for human immunodeficiency virus (HIV) at screening
  • Infection with hepatitis B or hepatitis C viruses
  • History of irregular bowel movements
  • History of herpes zoster
  • A positive tuberculosis test at screening or history of incompletely treated or untreated tuberculosis
  • History or presence of alcoholism or drug abuse within the past 2 years prior to dosing
  • Participation in another clinical study within 30 days prior to dosing

研究组 & 干预措施

Investigational Product

Experimental

[14C]-CTP-543

干预措施: [14C]-CTP-543 (Drug)

结局指标

主要结局

CTP-543 metabolite PK: Tmax

时间窗: Pre-dose, 0.5, 1, 1.5, 2, 4, 8, 12, 24, 36, 48, 72, 96 hours post-dose

Time for Cmax

Mass balance: Calculation of percent of total radioactivity recovered in feces

时间窗: From time zero up to 96 hours post-dose following oral administration of [14C]-CTP-543 up to Day 15

CTP-543 PK: Cmax

时间窗: Pre-dose, 0.5, 1, 1.5, 2, 4, 8, 12, 24, 36, 48, 72, 96 hours post-dose

Maximum plasma concentration

CTP-543 PK: AUClast

时间窗: Pre-dose, 0.5, 1, 1.5, 2, 4, 8, 12, 24, 36, 48, 72, 96 hours post-dose

Area under the plasma concentration time profile from time 0 to time of the last quantifiable concentration (Clast)

CTP-543 metabolite PK: AUC0-last

时间窗: Pre-dose, 0.5, 1, 1.5, 2, 4, 8, 12, 24, 36, 48, 72, 96 hours post-dose

Area under the plasma concentration time profile from time 0 to time of the last quantifiable concentration (Clast)

CTP-543 PK: CL/F

时间窗: Pre-dose, 0.5, 1, 1.5, 2, 4, 8, 12, 24, 36, 48, 72, 96 hours post-dose

Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood (rate at which a drug is metabolized or eliminated by normal biological processes).

CTP-543 metabolite PK: t1/2

时间窗: Pre-dose, 0.5, 1, 1.5, 2, 4, 8, 12, 24, 36, 48, 72, 96 hours post-dose

Total radioactivity in whole blood

时间窗: Pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96 hours post-dose

CTP-543 PK: Tmax

时间窗: Pre-dose, 0.5, 1, 1.5, 2, 4, 8, 12, 24, 36, 48, 72, 96 hours post-dose

Time for Cmax

CTP-543 PK: AUCinf

时间窗: Pre-dose, 0.5, 1, 1.5, 2, 4, 8, 12, 24, 36, 48, 72, 96 hours post-dose

Area under the plasma concentration time profile from time 0 to infinity

CTP-543 metabolite PK: AUCinf

时间窗: Pre-dose, 0.5, 1, 1.5, 2, 4, 8, 12, 24, 36, 48, 72, 96 hours post-dose

Area under the plasma concentration time profile from time 0 to infinity

Total [14C]: urine

时间窗: Pre-dose up to 336 hours post-dose

Total radioactivity excreted into the urine from time zero to the time of last measurable concentration following oral administration of \[14C\]-CTP-543

Total [14C]: feces

时间窗: Pre-dose up to 336 hours post-dose

Total radioactivity excreted into the feces from time zero to the time of last measurable concentration following oral administration of \[14C\]-CTP-543

CTP-543 metabolite PK: Cmax

时间窗: Pre-dose, 0.5, 1, 1.5, 2, 4, 8, 12, 24, 36, 48, 72, 96 hours post-dose

Maximum plasma concentration

CTP-543 PK: t1/2

时间窗: Pre-dose, 0.5, 1, 1.5, 2, 4, 8, 12, 24, 36, 48, 72, 96 hours post-dose

CTP-543 PK: Vz/F

时间窗: Pre-dose, 0.5, 1, 1.5, 2, 4, 8, 12, 24, 36, 48, 72, 96 hours post-dose

Apparent volume of distribution following oral administration

Total radioactivity in plasma

时间窗: Pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96 hours post-dose

Mass balance: Calculation of percent of total radioactivity recovered in urine

时间窗: From time zero up to 96 hours post-dose following oral administration of [14C]-CTP-543 up to Day 15

次要结局

  • Number of Participants With Clinically Significant Change From Baseline in Respiratory Rate(Screening, Pre-dose, 2, 8, 48 hours post-dose)
  • Number of Participants With Clinically Significant Change From Baseline in Serum Chemistry(Screening, Check-in, 8, 24 hours postdose)
  • Number of Participants With Clinically Significant Change From Baseline in Electrocardiogram - QT Interval(Screening, Pre-dose, 48 hours post-dose)
  • Number of Participants With Clinically Significant Change From Baseline in Coagulation(Screening, Check-in, 8, 24 hours postdose)
  • Number of Participants With Clinically Significant Changes to the Physical Examination(Screening up to Day 15)
  • Number of Participants With Clinically Significant Change From Baseline in Urinalysis(Screening, Check-in, 8, 24 hours postdose)
  • Number of Participants With Clinically Significant Change From Baseline in Heart Rate(Screening, Pre-dose, 2, 8, 48 hours post-dose)
  • Number of Participants With Clinically Significant Change From Baseline in Blood Pressure(Screening, Pre-dose, 2, 8, 48 hours post-dose)
  • Number of Participants With Clinically Significant Change From Baseline in Temperature(Screening, Pre-dose, 2, 8, 48 hours post-dose)
  • Number of Participants With Clinically Significant Change From Baseline in Electrocardiogram - P Wave(Screening, Pre-dose, 48 hours post-dose)
  • Adverse events(Screening up to Day 15)
  • Number of Participants With Clinically Significant Change From Baseline in Hematology(Screening, Check-in, 8, 24 hours postdose)
  • Number of Participants With Clinically Significant Change From Baseline in Electrocardiogram - QRS Complex(Screening, Pre-dose, 48 hours post-dose)

研究者

发起方
Concert Pharmaceuticals
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验